Brokerages Set ALX Oncology Holdings Inc. (NASDAQ:ALXO) Target Price at $4.14

ALX Oncology Holdings Inc. (NASDAQ:ALXO) has been assigned an average recommendation of “Moderate Buy” from the seven analysts that are covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year price target among analysts that have covered the stock in the last year is $4.14.

ALXO has been the topic of a number of recent analyst reports. HC Wainwright reiterated a “buy” rating and set a $5.00 price target on shares of ALX Oncology in a report on Friday, March 7th. Piper Sandler lifted their target price on ALX Oncology from $8.00 to $9.00 and gave the stock an “overweight” rating in a research note on Thursday, March 6th. UBS Group reduced their price target on shares of ALX Oncology from $4.00 to $2.20 and set a “buy” rating for the company in a research report on Monday, January 27th. Stifel Nicolaus lowered their price objective on shares of ALX Oncology from $3.00 to $1.50 and set a “hold” rating on the stock in a research report on Friday, March 7th. Finally, Jefferies Financial Group raised shares of ALX Oncology from a “hold” rating to a “buy” rating and increased their target price for the company from $2.00 to $3.00 in a research report on Thursday, March 6th.

ALX Oncology Stock Down 0.2 %

ALX Oncology stock opened at $0.83 on Friday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 4.82 and a current ratio of 4.82. The stock has a market cap of $43.78 million, a PE ratio of -0.28 and a beta of 1.01. ALX Oncology has a fifty-two week low of $0.83 and a fifty-two week high of $17.83. The firm’s 50-day simple moving average is $1.31 and its 200 day simple moving average is $1.56.

Institutional Trading of ALX Oncology

Hedge funds and other institutional investors have recently modified their holdings of the business. JSF Financial LLC purchased a new position in ALX Oncology in the 4th quarter valued at approximately $29,000. GSA Capital Partners LLP purchased a new position in shares of ALX Oncology in the third quarter valued at $88,000. Barclays PLC raised its stake in shares of ALX Oncology by 243.6% during the 3rd quarter. Barclays PLC now owns 59,502 shares of the company’s stock valued at $107,000 after purchasing an additional 42,185 shares during the period. Sei Investments Co. purchased a new stake in ALX Oncology during the 4th quarter worth about $102,000. Finally, Bridgeway Capital Management LLC bought a new position in ALX Oncology in the 4th quarter worth about $125,000. Institutional investors own 97.97% of the company’s stock.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.